← Back to Search

Monoclonal Antibodies

ladiratuzumab vedotin for Breast Cancer

Phase 1
Waitlist Available
Research Sponsored by Seagen Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 8 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will study the safety and effectiveness of a new cancer drug, given alone or with another drug.

Eligible Conditions
  • Breast Cancer
  • Breast cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 8 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 8 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of adverse events
Incidence of laboratory abnormalities
Secondary study objectives
Duration of response (DOR)
Objective response rate (ORR)
Overall survival (OS)
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: LV MonotherapyExperimental Treatment1 Intervention
LV will be given at the recommended dose (at or below the monotherapy MTD determined in the LV dose escalation arm).
Group II: LV Dose EscalationExperimental Treatment1 Intervention
Group III: LV + TrastuzumabExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ladiratuzumab vedotin
2013
Completed Phase 1
~290
Trastuzumab
2014
Completed Phase 4
~5190

Find a Location

Who is running the clinical trial?

Seagen Inc.Lead Sponsor
210 Previous Clinical Trials
74,140 Total Patients Enrolled
5 Trials studying Breast Cancer
3,066 Patients Enrolled for Breast Cancer
Phillip Garfin, MDStudy DirectorSeagen Inc.
Zejing Wang, MD, PhDStudy DirectorSeagen Inc.
3 Previous Clinical Trials
1,277 Total Patients Enrolled
~24 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top